<DOC>
	<DOCNO>NCT01182610</DOCNO>
	<brief_summary>This open-label , Phase II , single-stage study evaluate use panitumumab , paclitaxel , carboplatin 5FU induction regimen subject gastroesophageal adenocarcinoma . The expectation combination increase potential overall survival incorporate novel biologic therapy neoadjuvant set decrease potential surgical mortality eliminate pre-operative radiation therapy .</brief_summary>
	<brief_title>Panitumumab , Paclitaxel , Carboplatin 5FU Treatment Potentially Resectable Gastroesophageal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Biopsyproven adenocarcinoma distal esophagus , gastroesophageal junction , proximal stomach ( within 5cm gastroesophageal junction ) No prior treatment disease AJCC ( American Joint Committee Cancer ) clinical stage II IVA , potentially resectable disease Measurable disease per RECIST 1.0 criterion Medically fit surgery ; surgical consultation encourage prior initiation treatment ECOG ( Eastern Cooperative Oncology Group ) performance status 0 1 Male female ; age equal great 18 year Life expectancy great 3 month Good organ , metabolic , bone marrow , pulmonary function specify protocol Functioning central venous access device prior treatment initiation Women childbearing potential men must agree use adequate contraception prior study entry least 6 month follow last administration panitumumab Ability understand willingness sign write IRB ( Institutional Review Board ) approve informed consent Prior treatment disease History another primary cancer except curatively treat situ cervical cancer , curatively resect nonmelanoma skin cancer , primary solid tumor curatively treat active disease present treatment administer least 5 year prior enrollment History know presence central nervous system metastases History allergic reaction attribute compound similar chemical biologic composition panitumumab , paclitaxel , carboplatin , 5FU Prior antiEGFrantibody therapy treatment small molecule EGFr inhibitor Systemic chemotherapy , hormonal therapy , immunotherapy , experimental approve proteins/antibodies within 30 day prior enrollment Chronic use immunosuppressive agent exception corticosteroid Any investigational agent therapy within 30 day prior enrollment Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement History interstitial lung disease , e.g. , pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan History medical psychiatric condition laboratory abnormality opinion investigator may increase risk associate study participation investigational product ( ) administration may interfere interpretation result Unwilling unable comply study requirement Female test positive serum urine pregnancy test breast feed Known positive test ( ) human immunodeficiency virus infection , hepatitis C virus , acute chronic active hepatitis B infection Major surgery within 28 day minor surgery within 7 day prior treatment . Placement central venous access device le one day prior treatment start Male female childbearing potential ( woman postmenopausal less 52 week , surgically sterilize , abstinent ) consenting use adequate contraception prior study entry least 6 month follow last administration panitumumab Arterial ischemic event ( myocardial infarction , stroke ) within 3 month prior enrollment Ongoing therapeutic anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>